BIK-E715E / BIK Therapeutics - LARVOL DELTA

BIK-E715E, an integrin-targeting ligand-drug conjugate equipped with a novel drug delivery system, demonstrates enhanced antitumor efficacy in glioblastoma (AACR 2025) - "These data demonstrate that BIK-E715E is an attractive drug candidate for glioblastoma, equipped with a novel drug delivery system. Further, they also suggest that our ELiTE-DDS platform has great potential for enhancing target-selective intracellular delivery of therapeutic agents across the BBB."

Clinical • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CHEK1

BIK Therapeutics Announces Preclinical Study Results of Anticancer Agent BIK-E715E at AACR [Google translation] (HIT News) - "According to the company, BIK-E715E is a new drug candidate for glioblastoma that combines ELiTE-DDS drug delivery technology with a drug complex consisting of an integrin-targeting peptide overexpressed in glioblastoma cancer cells and a cytotoxic anticancer agent. ELiTE-DDS is BIK Therapeutics' unique drug delivery platform technology that enhances the target binding affinity and intracellular delivery of drugs....Through this presentation, BIK Therapeutics will present BIK-E715E’s superior cancer cell targeting ability, enhanced intracellular drug delivery efficiency, and higher anticancer efficacy in animal models compared to existing cytotoxic anticancer agents. In particular, it will emphasize BIK-E715E’s high blood-brain barrier penetration rate through ELiTE-DDS drug delivery technology."

Preclinical • Glioblastoma